Trinity, FL

Bayside Clinical Research

Hypertriglyceridemia

ISIS 678354

Olezarsen

Ionis Pharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Bayside Clinical Research | Trinity, FL

Site insights

Work at this site?

Active trials

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Trial sponsors